ADIL ADIAL PHARMACEUTICALS, INC.
AI brief AI-written, not reviewed by a person
Latest available figures show cash and equivalents at 5,881,217 USD as of 2025-12-31, with a year-ago comparison of 3,750,525 USD at 2024-12-31; diluted EPS (year) is -11.93 USD per share for 12 months to 2025-12-31 versus -68.01 USD for 12 months to 2024-12-31. Stockholders’ equity is negative at -38,377,000 USD as of 2026-06-30, contrasting with a positive 5,277,000 USD at 2025-12-31; net income (year) is -7,978,000,000,000.00 USD for 12 months to 2025-12-31 versus -13,197,000,000,000.00 USD for 12 months to 2024-12-31.
- Cash and equivalents at 2025-12-31: 5,881,217 USD; 2025-09-30: 4,606,289; 2025-06-30: 5,914,980; 2025-03-31: 2,365,780; 2024-12-31: 3,750,525. [1]
- Diluted EPS (year) 12 months to 2025-12-31: -11.93 USD/shares; 12 months to 2024-12-31: -68.01 USD/shares. [1]
- Diluted EPS (quarter) 3 months to 2026-06-30: -11.25 USD/shares; 3 months to 2026-03-31: -1.48; 3 months to 2025-09-30: -0.08; 3 months to 2025-06-30: -4.61; 3 months to 2025-03-31: -8.52. [1]
- Stockholders’ equity at 2026-06-30: -38,377,000 USD; at 2026-03-31: 3,717,000; at 2025-12-31: 5,277,000; at 2025-09-30: 4,505,091; at 2025-06-30: 5,590,000. [1]
- Net income (year) 12 months to 2025-12-31: -7,978,000,000,000.00 USD; 12 months to 2024-12-31: -13,197,000,000,000.00 USD. [1]
- Operating cash flow (year) 12 months to 2025-12-31: -6,492,603 USD; 12 months to 2024-12-31: -6,922,306 USD. [1]
- Operating cash flow (quarter) 3 months to 2026-03-31: -1,612,401 USD; 3 months to 2025-03-31: -1,585,393 USD. [1]
- Operating income (year) 12 months to 2025-12-31: -7,799,462 USD; 12 months to 2024-12-31: -8,284,457 USD. [1]
- Operating income (quarter) 3 months to 2026-06-30: -52,025,000 USD; 3 months to 2026-03-31: -2,001,481 USD; 3 months to 2025-09-30: -1,764,078 USD; 3 months to 2025-06-30: -1,882,000 USD; 3 months to 2025-03-31: -2,267,293 USD. [1]
- Shares outstanding at 2026-08-12: 2,625,890 shares; at 2026-03-04: 1,427,970 shares; at 2025-11-07: 23,987,587 shares; at 2025-08-08: 21,828,215 shares; at 2025-02-28: 6,574,588 shares. [1]
- Total assets at 2026-06-30: 29,089,000 USD; at 2026-03-31: 5,227,321 USD; at 2025-12-31: 6,674,000 USD; at 2025-09-30: 5,659,847 USD; at 2025-06-30: 6,801,703 USD. [1]
- Total liabilities at 2026-06-30: 28,933,000 USD; at 2026-03-31: 1,510,071 USD; at 2025-12-31: 1,397,000 USD; at 2025-09-30: 1,154,756 USD; at 2025-06-30: 1,211,027 USD. [1]
- Source 13 and 14 indicate filings (10-Q/A and 8-K) around Oct 2026 related to ADIAL PHARMACEUTICALS, INC., supporting the contemporaneous periodic filings referenced. [1][2]
Written by OpenVibe.AI from the SEC numbers and filings on this page, not reviewed by a person. Informational only; not investment advice. Written from figures and filings up to (gpt-5-nano-2025-08-07).
What the sources did not support
- Some figures appear to be anomalously large innet income (e.g., -7,978,000,000,000.00 USD) and years with inconsistent magnitude; the dataset does not include corroborating notes or currency formatting context to verify these values.
- No explicit period labels for some observations beyond those provided; exact filing dates for 2026-06-30 items rely on the cited 111121 filing blocks but are not separately itemized here.
Observations
| Metric | Value | Observed | Source | Retrieved | Freshness |
|---|---|---|---|---|---|
| Net income (quarter) (3 months to 2026-06-30) | -51,989,000 USD | sec-companyfacts | current | ||
| Net income (year) (12 months to 2025-12-31) | -7,978,000,000,000 USD | sec-companyfacts | current | ||
| Operating income (quarter) (3 months to 2026-06-30) | -52,025,000 USD | sec-companyfacts | current | ||
| Operating income (year) (12 months to 2025-12-31) | -7,799,462 USD | sec-companyfacts | current | ||
| Diluted EPS (quarter) (3 months to 2026-06-30) | -11.25 USD/shares | sec-companyfacts | current | ||
| Diluted EPS (year) (12 months to 2025-12-31) | -11.93 USD/shares | sec-companyfacts | current | ||
| Operating cash flow (quarter) (3 months to 2026-03-31) | -1,612,401 USD | sec-companyfacts | current | ||
| Operating cash flow (year) (12 months to 2025-12-31) | -6,492,603 USD | sec-companyfacts | current | ||
| Total assets (at 2026-06-30) | 29,089,000 USD | sec-companyfacts | current | ||
| Total liabilities (at 2026-06-30) | 28,933,000 USD | sec-companyfacts | current | ||
| Stockholders' equity (at 2026-06-30) | -38,377,000 USD | sec-companyfacts | current | ||
| Cash and equivalents (at 2025-12-31) | 5,881,217 USD | sec-companyfacts | current | ||
| Shares outstanding (at 2026-08-12) | 2,625,890 shares | sec-companyfacts | current |
Context
No reviewed context has been published for ADIL. The observations and documents below are shown as their sources stated them.
Documents
Source freshness
| Source | Freshness | Last successful fetch | Stale after | Sources reports |
|---|---|---|---|---|
| SEC EDGAR: company financial facts (XBRL) sec-companyfacts | current | 10080 min | ok | |
| SEC EDGAR: latest XBRL filings sec-xbrl-filings | current | 45 min | healthy |
Watch this instrument
Sign in to add ADIL to a private watchlist or to get an alert when a new document or observation arrives.
Machine-readable: ADIL.json (the same data with every timestamp and source).
Information only — not investment advice; no trading here. OpenVibe.Trade holds no money or assets, takes no orders and gives no personal recommendations.